EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
5.05
-0.37 (-6.83%)
At close: Apr 1, 2025, 4:00 PM
5.28
+0.23 (4.53%)
After-hours: Apr 1, 2025, 4:26 PM EDT
EyePoint Pharmaceuticals Stock Forecast
EYPT's stock price has decreased by -74.94% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for EyePoint Pharmaceuticals stock have an average target of 25.71, with a low estimate of 15 and a high estimate of 33. The average target predicts an increase of 409.11% from the current stock price of 5.05.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for EyePoint Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +553.47% | Mar 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +335.64% | Mar 6, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +553.47% | Feb 6, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +553.47% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +335.64% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
18.00M
from 43.27M
Decreased by -58.40%
Revenue Next Year
13.02M
from 18.00M
Decreased by -27.69%
EPS This Year
-2.80
from -2.32
EPS Next Year
-2.77
from -2.80
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 52.7M | 49.3M | 91.4M | ||
| Avg | 18.0M | 13.0M | 57.0M | ||
| Low | n/a | n/a | 3.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.7% | 173.7% | 601.8% | ||
| Avg | -58.4% | -27.7% | 337.7% | ||
| Low | - | - | -70.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.15 | -1.53 | -0.66 | ||
| Avg | -2.80 | -2.77 | -2.37 | ||
| Low | -3.08 | -3.64 | -3.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.